Raymond James Financial Services Advisors, Inc. Krystal Biotech, Inc. Transaction History
Raymond James Financial Services Advisors, Inc.
- $73.5 Billion
- Q3 2024
A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 1,348 shares of KRYS stock, worth $247,924. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,348
Previous 1,313
2.67%
Holding current value
$247,924
Previous $241,000
1.66%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding KRYS
# of Institutions
301Shares Held
24.4MCall Options Held
388KPut Options Held
233K-
Black Rock Inc. New York, NY3.95MShares$726 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.88MShares$529 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.63MShares$483 Million6.0% of portfolio
-
State Street Corp Boston, MA1.28MShares$235 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA879KShares$162 Million0.02% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.72B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...